



SDI Review Form 1.6

Journal Name:	<u>Journal of Advances in Medical and Pharmaceutical Sciences</u>
Manuscript Number:	Ms_JAMPS_18954
Title of the Manuscript:	Design of COX-1 Inhibitors Utilizing Class I Isosteres, Class II Isosteres, and Nonclassical Bioisosteres for Substituent Substitution on Proved Parent Structures
Type of the Article	Original Research Article

General guideline for Peer Review process:

This journal's peer review policy states that **NO** manuscript should be rejected only on the basis of '**lack of Novelty**', provided the manuscript is scientifically robust and technically sound.

To know the complete guideline for Peer Review process, reviewers are requested to visit this link:

(<http://www.sciencedomain.org/page.php?id=sdi-general-editorial-policy#Peer-Review-Guideline>)



SDI Review Form 1.6

PART 1: Review Comments

	Reviewer's comment	Author's comment <i>(if agreed with reviewer, correct the manuscript and highlight that part in the manuscript. It is mandatory that authors should write his/her feedback here)</i>
<u>Compulsory</u> REVISION comments	The study is a very good attempt, however, the report should be summarised to make it concise. A brief explanation of processes or approach would be vital to allow for further research activity	I have streamlined the CONCLUSION and revised the last paragraph in the INTRODUCTION to clarify and summarize the actual approach to the design of these derivatives of meclofenamic and tolfenamic acid. The "approach" to the study is condensed and presented in the last paragraph of the INTRODUCTION (lines 48 to 54) and the CONCLUSION. There is a great amount of data and calculations that must be presented in any sort of analysis of this type. The categories of derivatives (Class I isosteres, Class II isosteres, and Bioisosteres) MUST BE DIFFERENTIATED in order to have a distinction and full description of drug-likeness. Providing full distinction will help readers understand the capabilities and potential of these derivatives that spring from meclofenamic and tolfenamic acid.
<u>Minor</u> REVISION comments		
<u>Optional/General</u> comments		